Srinivas Akkaraju, M.D., Ph.D. has served on our board of directors since February 2021. Dr. Akkaraju has served as Managing General Partner of Samsara BioCapital, a venture capital firm, since he founded the firm in 2017. From April 2013 to March 2017, Dr. Akkaraju was a General Partner and then a Senior Advisor of Sofinnova Ventures, a venture capital firm focused on the life sciences industry. From January 2009 until April 2013, Dr. Akkaraju was a Managing Director of New Leaf Venture Partners, an investment firm focused on the healthcare technology sector. From 2006 to 2008, Dr. Akkaraju served as a Managing Director of Panorama Capital, a venture capital firm that he co-founded along with other members of the former venture capital investment team of J.P. Morgan Partners, a private equity division of JPMorgan Chase & Co. Prior to co-founding Panorama Capital, Dr. Akkaraju was with J.P. Morgan Partners, which he joined in 2001 and of which he became a partner in 2005. From 1998 to 2001, Dr. Akkaraju worked in business and corporate development at Genentech, Inc. (now a member of the Roche Group), a biotechnology company. Dr. Akkaraju has been a director of publicly-traded biopharmaceutical companies Intercept Pharmaceuticals since October 2012, Jiya Acquisition Corp. (where he also serves as Chairman) since November 2020, and Syros Pharmaceuticals, Inc. since June 2017. Dr. Akkaraju also serves on the board of directors of a number of private companies. During the past five years, Dr. Akkaraju previously served as a director of Aravive, Inc. (formerly Versartis, Inc.), aTyr Pharma, Inc., Principia Biopharma Inc., and Seattle Genetics, Inc. (now Seagen Inc.). Dr. Akkaraju received his M.D. and a Ph.D. in Immunology from Stanford University and holds undergraduate degrees in Biochemistry and Computer Science from Rice University.
What is Srinivas Akkaraju's net worth?
The estimated net worth of Srinivas Akkaraju is at least $47.37 million as of December 5th, 2025. Akkaraju owns 1,265,253 shares of Mineralys Therapeutics stock worth more than $47,371,072 as of December 12th. This net worth approximation does not reflect any other assets that Akkaraju may own. Learn More about Srinivas Akkaraju's net worth.
How do I contact Srinivas Akkaraju?
Has Srinivas Akkaraju been buying or selling shares of Mineralys Therapeutics?
Srinivas Akkaraju has not been actively trading shares of Mineralys Therapeutics during the past quarter. Most recently, on Thursday, September 4th, Srinivas Akkaraju bought 588,235 shares of Mineralys Therapeutics stock. The stock was acquired at an average cost of $25.50 per share, with a total value of $14,999,992.50. Following the completion of the transaction, the director now directly owns 588,235 shares of the company's stock, valued at $14,999,992.50. Learn More on Srinivas Akkaraju's trading history.
Who are Mineralys Therapeutics' active insiders?
Are insiders buying or selling shares of Mineralys Therapeutics?
In the last twelve months, Mineralys Therapeutics insiders bought shares 4 times. They purchased a total of 3,661,001 shares worth more than $70,599,973.50. In the last twelve months, insiders at the sold shares 25 times. They sold a total of 1,673,513 shares worth more than $65,594,244.11. The most recent insider tranaction occured on November, 20th when Director Brian Taylor Slingsby sold 1,000,000 shares worth more than $43,350,000.00. Insiders at Mineralys Therapeutics own 25.6% of the company.
Learn More about insider trades at Mineralys Therapeutics. Information on this page was last updated on 11/20/2025.
